Metabolic factors and oxidative stress in osteoarthritis: a case–control study

Tootsi, Kaspar; Märtson, Aare; Kals, Jaak; Paapstel, Kaido; Zilmer, Mihkel

doi:10.1080/00365513.2017.1354255

Cited by 35 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence from previous studies indicated that oxidative stress may have a critical role in the pathophysiology of OA. There are many studies investigating levels of oxidative markers in the blood and the SF samples of OA patients . However, the results are still controversial and it is not fully understood whether SF increases or decreases the status of oxidative stress .…”

Section: Discussionmentioning

confidence: 99%

“…There are many studies investigating levels of oxidative markers in the blood and the SF samples of OA patients. 32,34,35 However, the results are still controversial and it is not fully understood whether SF increases or decreases the status of oxidative stress. 36,37 Moreover, it is difficult to discriminate the difference among the statuses of oxidative stress in different stages of knee OA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of UCMA levels in serum and synovial fluid with severity of knee osteoarthritis

et al. 2019

View full text Add to dashboard Cite

Aim Osteoarthritis (OA) is one of the most common joint diseases causing physical disability in the aged population. OA pathogenesis is not fully known and yet there are no effective therapeutic options against OA. Upper Zone of Growth Plate and Cartilage Matrix Associated (UCMA) is a member of vitamin K‐dependent protein family, and is involved in inflammation, cardiovascular diseases, cancer, and OA. In the present study, our aim was to detect serum and synovial fluid (SF) levels of UCMA and to analyze their correlation with radiographic findings and symptomatic severity in OA patients as well as the correlation between oxidative stress levels and SF UCMA levels. Methods Forty OA patients with cartilage degeneration and 20 patients with other knee joint disorders (non‐OA control) were included in the present study. We used the Kellgren‐Lawrence (KL) classification and Western Ontario McMaster University Osteoarthritis Index (WOMAC) scores to assess radiographic grading and symptomatic severity of OA, respectively. UCMA levels were measured in SF and serum. And also oxidative stress markers were analyzed in SF. Results SF UCMA levels of OA patients were higher compared to those of the non‐OA control group and were positively correlated with radiographic finding and symptomatic severity of OA. However, there was no significant correlation between oxidative markers of SF and the KL grade, WOMAC scores, and SF UCMA levels in OA patients. Conclusion There is a close connection between UCMA SF levels and symptomatic and radiographic severities of knee OA. Therefore, UCMA can be a promising biomarker in the diagnosis and/or prognosis of OA disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association of UCMA levels in serum and synovial fluid with severity of knee osteoarthritis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…ox-LDL and oxidative stress parameters were reported to be higher in KOA patients and correlated with KOA severity 33 . Endstage HOA/KOA patients have increased levels of oxidative stress markers, decreased antioxidant capacity, impaired lipid metabolism, and dysglycemia 34 . Moreover, glycoprotein YKL-40, a potential marker for active inflammatory process, is involved in the pathogenesis of KOA synovitis 35 .…”

Section: Association With Clinical Scores and Changesmentioning

confidence: 99%

Osteoarthritis year in review 2018: biomarkers (biochemical markers)

Hosnijeh

Bierma-Zeinstra

Bay‐Jensen

2019

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

The aim of this narrative review is to summarize important findings from biochemical marker studies relevant to osteoarthritis (OA) in the context of new discoveries and clinical and scientific need. Design: We conducted a systematic search of electronic medical databases (Embase, Medline, Web of Science, Cochrane central) between 01-03-2017 and 31-03-2018. The search was restricted to human studies, English language and full text available publications while reviews were excluded. Only papers describing protein based biomarkers measured in human body fluids (blood, urine and synovial fluid (SF)) were included. Of the 992 papers, 86 were reviewed here, with inclusion primarily based on relevance to OA biochemical markers. Results: This review highlights a selection of studies based on their quality and perceived importance to the field mainly including those that 1 evaluate prognostic value of biomarkers for OA progression (i.e., biomarkers reflecting change in composition of joint tissues and biomarkers of inflammation) 2 , help in assessment of intervention efficacy, and 3 are innovative and uncover new candidate biomarkers, or use new approaches in biomarker discovery. Conclusions: Key findings and implications for possible clinical utility of biochemical markers are summarized and discussed. Given the paucity of robust biomarkers within the field, and the heterogeneity of the condition, enormous works are needed for development and validation of novel and clinically applicable biomarkers to reduce the impact of this highly prevalent and debilitating condition.

show abstract

“…Существует мнение, что повышение общего холесте-рина, ЛПНП и ТГ в сыворотке крови ассоциировано с развитием и прогрессированием ОА коленных суставов [38][39][40]. В нашем исследовании практически все паци-енты имели дислипидемию.…”

Section: Discussionunclassified

New Opportunities Therapy in Patients With Knee Joint Osteoarthritis and Metabolic Syndrome

Алексеева¹,

Таскина²,

Кашеварова³

et al. 2018

Med. sov.

View full text Add to dashboard Cite

5-10 years). Duration of the study was 9 months (6 months of therapy: 1 capsule (50 mg) per day for the first month, 2 capsules (100 mg) per day for the next 5 months, and follow-up for 3 months). Evaluation of the efficacy and safety of the treatment was conducted according to generally accepted criteria. All patients were underwent biochemical tests at the beginning and at the end of therapy. Results. The study resulted in a statistically significant reduction in pain when walking according to VAS as early as in 1 month from the beginning of treatment; the further significant improvement was observed during the entire 6-month therapy. Withdrawal of therapy (the observation period was 3 months) didn't increase the pain syndrome. Evaluation according to Womac index also revealed identical regularity. A statistically significant improvement in the quality of life according to EQ-5D was also identified during the whole period of observation. By the end of the therapy, 92.5% of the patients were OMERACT -OARSI -responders and 64.2% of patients had completely withdrawn from NSAID. Against the background of the therapy, there was a significant decrease in BMI, LDL, TG, glucose, uric acid levels. Conclusion: The data obtained make it possible to recommend diacerein as a basic therapy for OA in patients with MS. On the background of therapy, the patients showed statistically significantly reduction in pain, stiffness, the need for NSAIDs, improved the quality of life and the function of the joints. In addition, the body weight decreases reliably, the lipidogram, carbohydrate and protein metabolism parameters also improved.

show abstract

Metabolic factors and oxidative stress in osteoarthritis: a case–control study

Cited by 35 publications

References 38 publications

Association of UCMA levels in serum and synovial fluid with severity of knee osteoarthritis

Association of UCMA levels in serum and synovial fluid with severity of knee osteoarthritis

Osteoarthritis year in review 2018: biomarkers (biochemical markers)

New Opportunities Therapy in Patients With Knee Joint Osteoarthritis and Metabolic Syndrome

Contact Info

Product

Resources

About